title: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
abstract: OBJECTIVE
  Resistance to chemotherapy in ovarian cancer is frequently associated with mutations in the p53 gene. The adenovirus dl1520 (ONYX-015) with the E1B 55-kd gene deleted, allowing selective replication in and lysis of p53-deficient tumor cells, has shown preclinical efficacy against p53-deficient nude mouse-human ovarian carcinomatosis xenografts.
  
  
  METHODS
  We undertook a phase I trial of intraperitoneal dl1520 in patients with recurrent ovarian cancer. Sixteen women with recurrent/refractory ovarian cancer received 35 cycles (median, two cycles) of dl1520 delivered on days 1 through 5 in four dose cohorts: 1 x 10(9) plaque forming units (pfu), 1 x 10(10) pfu, 3 x 10(10) pfu, and 1 x 10(11) pfu.
  
  
  RESULTS
  The most common significant toxicities related to virus administration were flu-like symptoms, emesis, and abdominal pain. One patient receiving 1 x 10(10) pfu developed common toxicity criteria grade 3 abdominal pain and diarrhea, which was dose-limiting. The maximum-tolerated dose was not reached at 10(11) pfu, and at this dose level patients did not experience significant toxicity. There was no clear-cut evidence of clinical or radiologic response in any patient. Blood samples were taken for adenovirus DNA and neutralizing antibodies. Polymerase chain reaction data indicating presence of virus up to 10 days after the final (day 5) infusion of dl1520 are suggestive of continuing viral replication.
  
  
  CONCLUSIONS
  This article therefore describes the first clinical experience with the intraperitoneal delivery of any replication-competent/-selective virus in cancer patients.
authors.affiliation: Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom. pav1y@clinmed.gla.ac.uk
authors.forename: P A
authors.initials: PA
authors.lastname: Vasey
authors.forename: L N
authors.initials: LN
authors.lastname: Shulman
authors.forename: S
authors.initials: S
authors.lastname: Campos
authors.forename: J
authors.initials: J
authors.lastname: Davis
authors.forename: M
authors.initials: M
authors.lastname: Gore
authors.forename: S
authors.initials: S
authors.lastname: Johnston
authors.forename: D H
authors.initials: DH
authors.lastname: Kirn
authors.forename: V
authors.initials: V
authors.lastname: O'Neill
authors.forename: N
authors.initials: N
authors.lastname: Siddiqui
authors.forename: M V
authors.initials: MV
authors.lastname: Seiden
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000256:Adenoviridae / Q000502:physiology; D017501:Adenovirus E1B Proteins / Q000235:genetics*; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D019008:Drug Resistance, Neoplasm; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D014779:Virus Replication
chemical_list: D017501:Adenovirus E1B Proteins; D000914:Antibodies, Viral; D016159:Tumor Suppressor Protein p53